Gland surgery最新文献

{"title":"T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective.","authors":"Meghana Kesireddy, Jairam Krishnamurthy","doi":"10.21037/gs-2025-23","DOIUrl":"10.21037/gs-2025-23","url":null,"abstract":"","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"785-790"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the enigma: understanding the complex disease course of granulomatous mastitis and seeking ways to shorten it.","authors":"Jia Liu, Wei-Yi Lin, Qiu-Zhou Wang, Xiao-Qin Yang, Qing Lv, Qiu-Wen Tan","doi":"10.21037/gs-2024-557","DOIUrl":"10.21037/gs-2024-557","url":null,"abstract":"<p><strong>Background: </strong>Granulomatous mastitis is an infrequent and intricate ailment. Limited knowledge exists regarding how granulomatous mastitis progresses and its impact on disease management. We aim to prospectively capture symptoms in the general population to accurately ascertain the duration of illness and the prevalence of long-lasting symptoms.</p><p><strong>Methods: </strong>This study reports data from 169 prospectively enrolled real-world patients with pathologically confirmed granulomatous mastitis. Patients were enrolled after screening according to the inclusion and exclusion criteria. Patients were followed-up every 2-4 weeks during treatment, then every 3-6 months (Year 1) and 6-12 months (Year 2). Outcomes included symptom resolution, disease course, and relapse. Associations between clinical variables and outcomes were assessed using appropriate statistical models, with significance defined as P<0.05.</p><p><strong>Results: </strong>The median disease course of granulomatous mastitis was 257 days (range, 55-1,500 days), with the majority of disease regression occurring within a span of 6 months subsequent to diagnosis; 72.78% of patients preferred steroids as the initial treatment. The use of steroids was associated with a shorter disease course after adjusting for age, lump size, abscess, and sinus formation (P=0.02). Abscess formation was observed in 58.57% of patients. Notably, abscess formation during disease progression contributed to a prolonged disease course (358.67 <i>vs.</i> 278.24 days, P=0.03).</p><p><strong>Conclusions: </strong>Our findings highlighted the heterogeneity of granulomatous mastitis disease course and emphasized the importance of steroid usage in shortening disease course. Avoiding abscess and sinus formation, early steroid usage during granulomatous mastitis treatment might be beneficial. These evidences provide novel insights and supports the use of steroids in patients with granulomatous mastitis for modulating their immune response. Studies are urgently needed to further elucidate the role of steroid in granulomatous mastitis management.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"646-657"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of dynamic contrast-enhanced ultrasound in predicting cervical lymph node metastasis in papillary thyroid carcinoma patients with Hashimoto's thyroiditis.","authors":"Kairen Zhang, Dan Zhao, Ying Song, Xiaofeng Wu, Chenyang Jin, Fenglin Dong","doi":"10.21037/gs-2024-510","DOIUrl":"10.21037/gs-2024-510","url":null,"abstract":"<p><strong>Background: </strong>Hashimoto's thyroiditis (HT) and papillary thyroid carcinoma (PTC) commonly coexist. An accurate assessment of cervical lymph node metastasis (CLNM) is crucial for determining treatment options and predicting prognosis. However, traditional examination methods have certain limitations. This study aimed to investigate the potential utility of dynamic contrast-enhanced ultrasound (DCE-US) using VueBox^® software in assessing CLNM in patients with PTC coexisting with HT.</p><p><strong>Methods: </strong>A retrospective analysis was performed on the clinicopathological data and ultrasound characteristics of 180 thyroid cancer patients who underwent either biopsy or surgery from January 2022 to November 2023. The dataset was partitioned into training and validation sets with a 6:4 ratio. Statistical analyses, including <i>t</i>-tests, chi-squared tests, and rank-sum tests, were conducted to evaluate the data. Univariate analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariate logistic regression were employed to identify the predictive factors for CLNM. Based on these analyses, three predictive models were developed: Model 1, incorporating clinical factors; Model 2, integrating clinical and ultrasound factors; and Model 3, a combined model that included both clinical and ultrasound factors using DCE-US. The diagnostic performance of each model was assessed using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>The Model 3 exhibited superior performance compared to Models 1 and 2. Specifically, in the training set, Model 3 achieved an area under the curve (AUC) value of 0.924 [95% confidence interval (CI): 0.857-0.966], and in the validation set, the AUC value was 0.905 (95% CI: 0.813-0.962). These values were significantly higher (P<0.05) than those of Model 1, which had a training AUC of 0.724 (95% CI: 0.630-0.806) and a validation AUC of 0.677 (95% CI: 0.557-0.783), as well as Model 2, with a training AUC of 0.854 (95% CI: 0.773-0.915) and a validation AUC of 0.797 (95% CI: 0.683-0.883). Moreover, DCA indicated that Model 3 provided a greater net benefit than Models 1 and 2 in both the training and validation cohorts.</p><p><strong>Conclusions: </strong>The use of VueBox^® perfusion analysis in DCE-US provides additional value in predicting CLNM in PTC patients with HT. The integrated model, which combines clinical and ultrasound factors, is a valuable diagnostic tool.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"597-610"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between ultrasound-based hepatic steatosis grade and thyroid hormone levels.","authors":"Xuanxuan Zhang, Meijuan Jiang, Wei Zhu, Shouxing Xu, Wenqian Wang, Bin Ying, Xiaoting Chen, Shanshan Zhang, Jianlian Pan, Kai Zhang, Frank Tacke, Ju Dong Yang, Jian Chen","doi":"10.21037/gs-2025-62","DOIUrl":"10.21037/gs-2025-62","url":null,"abstract":"<p><strong>Background: </strong>Thyroid hormones impact on metabolic homeostasis, and low thyroid hormone levels, both systemically and hepatically, have been linked to hepatic steatosis. However, prior studies in this area often lacked quantification of steatosis. Ultrasound attenuation analysis (USAT) is a novel imaging technique for hepatic steatosis detection based on the attenuation coefficient. Our objective in this study was to assess the correlation between thyroid hormone levels and hepatic steatosis via the USAT attenuation coefficient in metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic hepatitis B (CHB) groups.</p><p><strong>Methods: </strong>This retrospective study included 86 patients with CHB and 45 patients with suspicious MASLD. Demographic information, biochemical parameters, and thyroid hormone levels were analyzed. The severity of steatosis in MASLD or CHB was assessed by USAT.</p><p><strong>Results: </strong>Patients in the MASLD group were more likely to have type 2 diabetes mellitus (T2DM) and hypertension as compared with those in the CHB group (P<0.05). The levels of triiodothyronine (T3) were significantly lower and the platelet counts higher in the MASLD group than in the CHB group (P<0.05). The body mass index (BMI), distance from skin to capsule, USAT values, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with hepatic steatosis were significantly higher than those in patients without hepatic steatosis (P<0.05). Logistic regression analysis indicated a correlation between free triiodothyronine (FT3) level and hepatic steatosis (P=0.04) as well as between free thyroxine (FT4) level and hepatic steatosis (P=0.045).</p><p><strong>Conclusions: </strong>Quantitative USAT evaluation suggested that hepatic steatosis is strongly correlated with thyroid hormones. These data emphasize the relevance of thyroid hormones for regulating hepatic lipid accumulation and metabolism.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"726-737"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a screening model for benign and malignant breast masses based on S-Detect and microvascular flow imaging.","authors":"Zhongguang Hou, Yunyun Zhan, Jiajia Wang, Mei Peng","doi":"10.21037/gs-2024-488","DOIUrl":"10.21037/gs-2024-488","url":null,"abstract":"<p><strong>Background: </strong>Imaging examination of a breast mass is essential for improving breast cancer detection. Previous screening models of benign and malignant breast masses demonstrated a high level of subjectivity due to the inability to conduct quantitative evaluations. Thus, this study aimed to construct an objective, convenient, and effective nomogram incorporating S-Detect and microvascular flow imaging (MVFI) to predict breast cancer risk.</p><p><strong>Methods: </strong>Female patients with breast masses detected by conventional ultrasound examinations at the Second Affiliated Hospital of Anhui Medical University between January 2021 and October 2024 were retrospectively analyzed. All patients underwent preoperative assessments with both S-Detect and MVFI. The pathological results served as the gold standard for diagnosis. After screening, a total of 724 breast masses from 712 patients were randomized into the training (506 masses) and validation (218 masses) groups. Univariate analysis assessed patient age, as well as the location, size, vascular index (VI), and S-Detect-based diagnosis of the masses. Risk factors for predicting breast cancer were screened using multivariate analysis. A nomogram prediction model was then constructed. Diagnostic performance, clinical utilization value, and calibration were determined using the receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and calibration curve, respectively. Nomogram risk was calculated for each breast mass for risk stratification.</p><p><strong>Results: </strong>The training group included 208 benign and 298 malignant masses, while the validation group comprised 85 benign and 133 malignant masses. Multivariate analysis demonstrated that mass size [odds ratio (OR) =1.08; P<0.001], age (OR =1.09; P<0.001), VI (OR =1.07; P<0.001), and S-Detect-based diagnosis (OR =28.37; P<0.001) were risk factors for predicting breast cancer. The area under the curve (AUC) for the nomogram model was significantly greater than that for S-Detect in both the training (0.93 <i>vs</i>. 0.82, P<0.001) and validation (0.91 <i>vs</i>. 0.82, P<0.001) groups. The diagnostic sensitivity and specificity of the nomogram were 93.3% and 79.8% in the training group, and 98.5% and 72.9% in the validation group, respectively. The optimal cut-off value for nomogram risk differentiation between the high-risk and low-risk sets was 0.495, with a significantly higher proportion of malignant breast masses in the high-risk set compared to that in the low-risk set (P<0.001).</p><p><strong>Conclusions: </strong>This novel nomogram model based on quantitative and objective ultrasound and clinical features can quantify the malignancy risk of breast masses, identify high-risk individuals, and provide a reference for further examinations.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"687-698"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant risk prediction of cystic-solid thyroid nodules using a comprehensive model integrating clinical and ultrasound features, ultrasound radiomics, and deep transfer learning.","authors":"Rongwei Liu, Haiyuan Li, Changwen Liu, Jinbo Peng, Ruizhi Gao, Hong Yang, Yun He","doi":"10.21037/gs-2024-551","DOIUrl":"10.21037/gs-2024-551","url":null,"abstract":"<p><strong>Background: </strong>The risk of malignancy in cystic-solid thyroid nodules (CSTN) varies greatly and may be underestimated. This study aimed to explore the value of a comprehensive model that integrates deep transfer learning (DTL), ultrasound radiomics, and clinical, and ultrasound features in predicting the risk of malignancy of CSTN.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 278 patients with CSTN confirmed by pathology from the First Affiliated Hospital of Guangxi Medical University from January 2023 to December 2023. Radiomics features were manually extracted from ultrasound images, and DTL features were extracted using deep learning networks. The least absolute shrinkage and selection operator (LASSO) regression was utilized to select non-zero coefficient features from radiomics and DTL features. The comprehensive model nomogram was constructed using a logistic regression algorithm that integrates clinical, ultrasound features, deep learning, and radiomics features. The predictive performance was assessed using the receiver operating characteristic (ROC) curve and the area under the curve (AUC), calibration curves, and decision curves. Subsequently, DeLong testing was performed for comparative analysis of the AUC, with parameter estimates including a 95% confidence interval (CI), and a P value of less than 0.05 was considered statistically significant.</p><p><strong>Results: </strong>The AUC of each model was compared, revealing that the comprehensive model outperformed the individual models in predicting the malignancy risk of CSTN, demonstrating good predictive performance with sensitivity and specificity of 87.50% and 82.90%, respectively. Additionally, the AUC of the comprehensive model in the testing set was 0.913 (95% CI: 0.844-0.982), which was higher than the radiomics model (0.913 <i>vs.</i> 0.898, P=0.67), and the DTL model (0.913 <i>vs.</i> 0.848, P=0.38). In the training set, the AUC was 0.973 (95% CI: 0.949-0.997), outperforming the radiomics model (0.973 <i>vs.</i> 0.926, P=0.09) and the DTL model (0.973 <i>vs.</i> 0.943, P=0.01).</p><p><strong>Conclusions: </strong>The novel comprehensive model based on ultrasound demonstrates excellent performance in predicting the malignancy risk of CSTN, providing clinicians with a preoperative non-invasive screening method to predict the malignancy risk of CSTN.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"584-596"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A web-based predictive model for secondary skin infections in breast cancer patients undergoing reconstruction.","authors":"Xuni Xu, Wanying Chen, Gaoyi Wang, Yaqin Zhou, Wenkai Pan, Yu Zhou, Wei Zhang","doi":"10.21037/gs-24-470","DOIUrl":"10.21037/gs-24-470","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is one of the most common malignancies in women worldwide, with surgical interventions such as mastectomy and implant-based reconstruction playing a key role in management. While implant-based reconstruction offers immediate breast contour restoration, complications such as infection, capsular contracture, and implant failure are influenced by patient-specific factors, including age, body mass index (BMI), smoking, and adjuvant therapies like radiation. This study aimed to develop a predictive model for postoperative skin infections to enhance personalized risk assessment and optimize surgical outcomes in BC patients.</p><p><strong>Methods: </strong>This retrospective study included 166 Chinese female patients with BC who underwent unilateral mastectomy followed by implant-based reconstruction. Univariate and multivariate logistic regression analyses were conducted to identify independent risk factors for postoperative skin infections. A nomogram was constructed based on significant variables, with its accuracy assessed using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>The 166 patients were divided into training and validation cohorts (6:4). Univariate analysis identified BMI, chemotherapy, radiotherapy, and prosthesis thickness as significant factors for postoperative skin infections. Multivariate analysis confirmed BMI, chemotherapy, and prosthesis thickness as independent risk factors. The predictive model demonstrated strong performance, with area under the curve (AUC) values of 0.87 and 0.812 for the training and validation cohorts, respectively. Calibration curves showed good agreement between predicted and observed outcomes, and DCA confirmed the model's clinical utility. A web-based calculator was developed to estimate infection risk (https://kevinpan.shinyapps.io/InfectionStatus/).</p><p><strong>Conclusions: </strong>BMI, prosthesis thickness, and chemotherapy are key factors influencing the risk of postoperative skin infections in BC patients undergoing implant-based reconstruction. The predictive model developed in this study provides a valuable tool for clinicians to assess risk and personalize treatment plans. Further studies with larger cohorts are needed to validate and refine the model for broader clinical use.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"699-713"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-dense adjuvant chemotherapy for high-risk early breast cancer: its role in the era of personalised oncology.","authors":"Constantinos Savva, Ramsey Cutress, Ellen Copson","doi":"10.21037/gs-2025-72","DOIUrl":"10.21037/gs-2025-72","url":null,"abstract":"","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"791-796"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation study of tumor-infiltrating lymphocytes (TILs) and subtypes analysis before and after neoadjuvant chemotherapy in triple-negative breast cancer.","authors":"Yan Zhao, Si-Juan Jiang, Jin-Lu Wang, Zong-Yu Xie, Xin Jin","doi":"10.21037/gs-2024-537","DOIUrl":"10.21037/gs-2024-537","url":null,"abstract":"<p><strong>Background: </strong>In recent years, neoadjuvant chemotherapy (NACT) has become an increasingly important treatment for triple-negative breast cancer (TNBC). As the most immunogenic subtype of breast cancer, it is imperative to comprehensively study the immune microenvironment of TNBC and the effects of NACT on it. Our study aims to address this need and provide valuable insights for the development of effective postoperative adjuvant treatment strategies.</p><p><strong>Methods: </strong>Samples were taken prior to and following NACT with docetaxel, epirubicin, and cyclophosphamide (TEC) from 71 TNBC patients who were included in this trial. We examined the clinicopathological alterations in patients before and after NACT treatment, assessed the impact of stromal tumor-infiltrating lymphocytes (sTILs) and immune biomarkers [CD8, CD4, CD3, FOXP3, CD20, CD163, programmed cell death ligand 1 (PD-L1)] on the efficacy of neoadjuvant therapy, and identified changes in NACT-induced immune subsets and specific immune biomarkers.</p><p><strong>Results: </strong>Our study revealed that tumor size, histological grade, Ki-67 status, and sTILs content in baseline clinical features, as well as CD3, CD4, and CD8 content before NACT, showed significant differences between pathological complete response (pCR) and non-pCR patients (P<0.05). The expression of sTILs and PD-L1 in residual lesions after NACT was found to be higher than before NACT. Univariate analysis indicated that the levels of sTILs, CD3, CD4, and CD8 immune subsets before NACT were correlated with pCR. Importantly, multivariate regression analysis demonstrated that sTILs and CD8 immune subsets before NACT served as independent predictors of TNBC neoadjuvant therapy (P<0.05), providing crucial insights into the individualized management of TNBC.</p><p><strong>Conclusions: </strong>The findings of this study suggest that increasing sTILs and CD8 can significantly enhance the neoadjuvant efficacy of TNBC. Furthermore, the addition of CD3 and CD8 immune subsets can substantially improve the efficacy of TNBC neoadjuvant prediction. The detection of relevant immune markers after neoadjuvant therapy holds great promise in providing more comprehensive and accurate prognostic and therapeutic information for TNBC patients.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"628-645"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical appraisal of the 2 mm threshold in ductal carcinoma in situ: methodological concerns in meta-analysis of margin width and local recurrence risk.","authors":"Mariam Rizk, Muharrem Oner, Kefah Mokbel","doi":"10.21037/gs-2025-108","DOIUrl":"10.21037/gs-2025-108","url":null,"abstract":"","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"14 4","pages":"771-775"},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}